Recent progress in hormonal therapy for advanced prostate cancer

Current Opinion in Urology

Volumn 16, Issue 3, 2006, Pages 173-178

  Daskivich, Timothy J ^a   Oh, William K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Androgen antagonists; Estrogens; Hormonal antineoplastic agents; Hormone dependent neoplasms; Prostatic neoplasms

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; BICALUTAMIDE; CONJUGATED ESTROGEN; CORTICOSTEROID; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; HYDROCORTISONE; INDOMETACIN; KETOCONAZOLE; MIFEPRISTONE; NILUTAMIDE; PC SPES; PROSTATE SPECIFIC ANTIGEN; WARFARIN;

ADRENAL SUPPRESSION; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION; CHRONOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; DARK ADAPTATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRY SKIN; EARLY INTERVENTION; ESTROGEN THERAPY; FRACTURE; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HEART DEATH; HIGH RISK PATIENT; HORMONE DEPENDENCE; HOT FLUSH; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; LIBIDO DISORDER; LIGHT ADAPTATION; LIVER TOXICITY; LOW DRUG DOSE; MASTALGIA; METABOLIC DISORDER; METASTASIS; MOOD CHANGE; NAUSEA; NAUSEA AND VOMITING; ORCHIECTOMY; OSTEOPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; THERAPY DELAY; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; FRACTURES, BONE; HORMONE ANTAGONISTS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33646948291     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000193392.77469.e2     Document Type: Review

References (29)

1. 2005 Cancer Facts and Figures. American Cancer Society; 2005.
2. Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer 2005; 4:38-44.
3. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294:238-244. This review provides a current and comprehensive review of major clinical studies of primary ADT.
4. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32:1126-1130.
5. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79:235-246.
6. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171:1141-1147.
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164. This large, retrospective study definitively characterizes the risk of fracture in patients treated with ADT.
8. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025-1033.
9. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159:149-153.
10. Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58:53-58.
11. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15:2928-2938.
12. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005; 96:791-795. This study is one of the first to characterize the efficacy of flutamide in treatment of patients with AIPC.
13. Nakabayashi M, Regan MM, Lifsey D, et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 2005; 96:783-786. This study substantiates the findings of two previous studies showing impressive biochemical response rates with nilutamide in the treatment of AIPC.
14. Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology 2001; 58:1016-1020.
15. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003; 169:1742-1744.
16. Davis NB, Ryan CW, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int 2005; 96:787-790. This phase II study adds to growing evidence that second-line nilutamide may not be as effective when used after failure of bicalutamide.
17. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157:1204-1207.
18. Millikan R, Baez L, Banerjee T, et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol 2001; 6:111-115.
19. Harris KA, Weinberg V, Bok RA, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002; 168:542-545.
20. Scholz M, Jennrich R, Strum S, et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005; 173:1947-1952. This retrospective study identifies variables that are predictive of success of ketoconazole therapy and overall survival, providing predictive and prognostic information to patients who are at an increasingly uncertain timepoint in their disease course.
21. Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 2002; 1:81-89.
22. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339:785-791.
23. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase Il trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004; 22:3705-3712.
24. Hedlund PO, Ala-Opas M, Brekkan E, et al. Scandinavian Prostatic Cancer Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002; 36:405-413.
25. Ockrim JL, Lalani EN, Laniado ME, et al. Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol 2003; 169:1735-1737.
26. Ockrim JL, Lalani el-N, Kakkar AK, Abel PD. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005; 174:527-533. This retrospective cohort study shows that transdermal estradiol decreases thrombophilic activation of clotting factors in patients with AIPC; it is significant given that thromboembolic risk has limited the application of oral estrogens such as DES.
27. Bland LB, Garzotto M, DeLoughery TG, et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005; 103:717-723. This phase II study supports earlier studies showing that transdermal estradiol therapy has virtually no associated thromboembolic risk; however, it showed low efficacy at the doses tested.
28. Oh WK, Manola J, Taplin ME, et al. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). ASCO 2006 Prostate Cancer Symposium [meeting abstract].
29. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004; 18:70-85.